Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Molecular Diagnostics Moves Into Prostate Cancer

Executive Summary

While the PSA test is still widely recognized as a valuable prostate cancer screening tool, its dismal accuracy record has created an acute need for more effective and informative alternatives, and the field of molecular diagnostics, based on gene-based biomarkers, is leading the charge.

You may also be interested in...

Claims And Counterclaims Abound In Highly Competitive Breast Cancer Genomics Market

Companies active in the breast cancer genomics market are waging a war of words and data to push their respective tests forward. With an expanding volume of data showing that genomic testing can save many patients from unnecessary chemotherapy treatment, and positive recommendations issued in major clinical practice guidelines, there is a compelling argument – from both a quality of care and overall economic standpoint – for physicians to use these tests, and strong growth is anticipated in this space going forward.

Cleveland Diagnostics: Improving The PSA Test

A new prostate cancer assay that uniquely defines blood-based biomarkers could restore confidence in the controversial PSA (prostate specific antigen) screening test. Cleveland Diagnostics Inc.’s PSA/SIA test detects cancer-specific changes to the three-dimensional structure of a PSA protein molecule, as opposed to merely measuring the amount of PSA in the blood via a standard PSA test.

Medical Device Patents Surging, Industry Players Forecast The Future

With recent changes to US patent laws, a landmark US Supreme Court decision, and the emergence of so-called “patent trolls” in the medical device community, it seems everyone is talking patents. Medical device patents and litigation are “booming,” according to industry experts, and medtech companies need to pay close attention.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts